IL-17 A correlates with disease progression in papillary thyroid carcinoma.
Disease progression
FoxP3
IL-17A
Papillary thyroid carcinoma
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
10 Aug 2023
10 Aug 2023
Historique:
received:
21
02
2023
accepted:
05
06
2023
medline:
14
8
2023
pubmed:
11
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Cancer progression can be promoted by chronic inflammation. Local immune response may be associated with favourable or unfavourable prognosis of Papillary Thyroid Carcinoma (PTC). Regulatory T (Treg) cells and T helper 17 (Th17) cells exert opposing function and their balance may have a vital role in promotion of tumor growth. Treg cells in tumor microenvironment (TME) may promote tumor progression and reduced survival of patients. Whereas, Th17 cells can promote or inhibit tumor progression depending on phenotypic characteristics of tumor. In this study, we aimed to analyse the kind of immune response developed and its prognostic impact in future therapeutics. Cytometric Bead Array (CBA) analysis of pro and anti-inflammatory cytokines (IFN-gamma, IL-2, IL-6, IL-17 A, TNF-alpha and IL-4, IL-10) was done in 15 PTC irrespective of Lymphocytic Thyroiditis (LT) and 16 Hashimoto's Thyroiditis (HT) cases. Immunohistochemical expression of FoxP3 and IL-17 A was studied in 27 cases of PTC with LT. Whereas, quantitative gene expression of both was analysed in 10 cases. All the pro-inflammatory cytokines showed mild elevation in PTC with LT. On IHC, IL-17 A expression was observed in 74% PTC with LT. Whereas, FoxP3 was present in only 40% cases. Also, IL-17 A expression was significantly associated with age group (> 45 years), tumor size ≤ 1 cm and disease progression. Increased expression of cytokines suggested correlation between inflammatory factors and progression of thyroid tumors. Along with this, the balance between IL-17 A and FoxP3 may play an important role in PTC development, prognosis and future management.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer progression can be promoted by chronic inflammation. Local immune response may be associated with favourable or unfavourable prognosis of Papillary Thyroid Carcinoma (PTC). Regulatory T (Treg) cells and T helper 17 (Th17) cells exert opposing function and their balance may have a vital role in promotion of tumor growth. Treg cells in tumor microenvironment (TME) may promote tumor progression and reduced survival of patients. Whereas, Th17 cells can promote or inhibit tumor progression depending on phenotypic characteristics of tumor. In this study, we aimed to analyse the kind of immune response developed and its prognostic impact in future therapeutics.
METHODS
METHODS
Cytometric Bead Array (CBA) analysis of pro and anti-inflammatory cytokines (IFN-gamma, IL-2, IL-6, IL-17 A, TNF-alpha and IL-4, IL-10) was done in 15 PTC irrespective of Lymphocytic Thyroiditis (LT) and 16 Hashimoto's Thyroiditis (HT) cases. Immunohistochemical expression of FoxP3 and IL-17 A was studied in 27 cases of PTC with LT. Whereas, quantitative gene expression of both was analysed in 10 cases.
RESULTS
RESULTS
All the pro-inflammatory cytokines showed mild elevation in PTC with LT. On IHC, IL-17 A expression was observed in 74% PTC with LT. Whereas, FoxP3 was present in only 40% cases. Also, IL-17 A expression was significantly associated with age group (> 45 years), tumor size ≤ 1 cm and disease progression.
CONCLUSIONS
CONCLUSIONS
Increased expression of cytokines suggested correlation between inflammatory factors and progression of thyroid tumors. Along with this, the balance between IL-17 A and FoxP3 may play an important role in PTC development, prognosis and future management.
Identifiants
pubmed: 37563607
doi: 10.1186/s13000-023-01362-4
pii: 10.1186/s13000-023-01362-4
pmc: PMC10413719
doi:
Substances chimiques
Cytokines
0
Forkhead Transcription Factors
0
Interleukin-17
0
FOXP3 protein, human
0
IL17A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Subventions
Organisme : Postgraduate Institute of Medical Education and Research, Chandigarh
ID : 71/2-Edu-16/119
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Diagn Pathol. 2019 Jun 4;14(1):52
pubmed: 31159823
Zhonghua Bing Li Xue Za Zhi. 2017 Mar 8;46(3):160-165
pubmed: 28297755
Thyroid. 2014 Feb;24(2):339-46
pubmed: 23915122
Pediatr Res. 2009 May;65(5 Pt 2):26R-31R
pubmed: 19218879
Cancer Res. 2003 Oct 15;63(20):6784-90
pubmed: 14583474
Immunity. 1994 Sep;1(6):447-56
pubmed: 7895156
Cancer. 1995 Dec 1;76(11):2312-8
pubmed: 8635037
J Thyroid Res. 2016;2016:6178921
pubmed: 27034885
Eur Arch Otorhinolaryngol. 2012 Feb;269(2):699-700
pubmed: 21922425
Endocr Relat Cancer. 2014 Jun;21(3):505-16
pubmed: 24623740
Clinics (Sao Paulo). 2012;67(5):483-8
pubmed: 22666793
Annu Rev Immunol. 2001;19:683-765
pubmed: 11244051
Mod Pathol. 2003 Nov;16(11):1117-23
pubmed: 14614051
Sci Rep. 2020 Jun 30;10(1):10651
pubmed: 32606302
Neuroendocrinology. 2012;95(4):267-76
pubmed: 22248635
J Hepatol. 2009 May;50(5):980-9
pubmed: 19329213
Front Endocrinol (Lausanne). 2022 Nov 28;13:931647
pubmed: 36518249
Exp Ther Med. 2018 Mar;15(3):2661-2666
pubmed: 29467858
Cancer Immunol Immunother. 2015 Aug;64(8):1011-9
pubmed: 25971541
Blood. 2009 Aug 6;114(6):1141-9
pubmed: 19470694
J Clin Endocrinol Metab. 2013 Feb;98(2):636-42
pubmed: 23293334
J Clin Invest. 2005 Apr;115(4):1068-81
pubmed: 15761501
Curr Opin Immunol. 2007 Apr;19(2):209-16
pubmed: 17276050
Biology (Basel). 2020 Nov 05;9(11):
pubmed: 33167343
J Cancer. 2020 Apr 27;11(14):4250-4260
pubmed: 32368308
Immunol Lett. 2004 Apr 30;93(1):39-43
pubmed: 15134897
Autoimmun Rev. 2014 Jun;13(6):668-77
pubmed: 24418308
Scand J Clin Lab Invest. 2015 Nov;75(7):539-48
pubmed: 26305420
Cancer Lett. 2015 Jan 1;356(1):114-25
pubmed: 23994343
Immunity. 2008 Apr;28(4):454-67
pubmed: 18400188
J Immunol. 2007 Feb 15;178(4):2155-62
pubmed: 17277120
Oncol Lett. 2017 Mar;13(3):1925-1931
pubmed: 28454345
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):395-404
pubmed: 20627675
J Clin Lab Anal. 2014 May;28(3):249-54
pubmed: 24478186
J Leukoc Biol. 2007 Feb;81(2):557-66
pubmed: 17053163
J Clin Endocrinol Metab. 2001 Mar;86(3):1346-54
pubmed: 11238531